These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31857994)

  • 21. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
    Litière S; de Vries EGE; Seymour L; Sargent D; Shankar L; Bogaerts J;
    Eur J Cancer; 2014 Jul; 50(10):1847-1853. PubMed ID: 24726734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
    Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
    Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
    Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
    Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
    Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.
    Shukuya T; Mori K; Amann JM; Bertino EM; Otterson GA; Shields PG; Morita S; Carbone DP
    J Thorac Oncol; 2016 Nov; 11(11):1927-1939. PubMed ID: 27496650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
    Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
    Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
    Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.
    Ferté C; Fernandez M; Hollebecque A; Koscielny S; Levy A; Massard C; Balheda R; Bot B; Gomez-Roca C; Dromain C; Ammari S; Soria JC
    Clin Cancer Res; 2014 Jan; 20(1):246-52. PubMed ID: 24240109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
    Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
    J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
    Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
    Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperprogression after immunotherapy.
    Abbas W; Rao RR; Popli S
    South Asian J Cancer; 2019; 8(4):244-246. PubMed ID: 31807489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.
    Wang Z; Liu C; Bai Y; Zhao X; Cui L; Peng Z; Zhang X; Wang X; Zhao Z; Li J; Shen L
    Front Oncol; 2021; 11():761110. PubMed ID: 34858840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.